# Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

> **NCT02165826** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1323 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Roflumilast Placebo
- **DRUG:** Standard of Care COPD Treatment

## Key facts

- **NCT ID:** NCT02165826
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-01
- **Primary completion:** 2015-09-01
- **Final completion:** 2015-09-01
- **Target enrollment:** 1323 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02165826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02165826, "Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02165826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*